Adalimumab in Pediatric Inflammatory Bowel Disease
1Department of Pediatrics, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, South Korea.
Frontiers in Pediatrics
|May 2, 2022
Summary
Adalimumab (ADL) offers significant benefits for pediatric inflammatory bowel disease (IBD), improving mucosal healing and remission. Therapeutic drug monitoring can further optimize ADL treatment effectiveness in children.
Area of Science:
- Pediatric Gastroenterology
- Inflammatory Bowel Disease (IBD) Therapeutics
- Biological Agents in Pediatrics
Background:
- Biological agents, particularly anti-tumor necrosis factor (TNF) agents, have revolutionized IBD treatment and improved patient prognosis.
- Pediatric IBD management is evolving, with several biological agents under investigation.
- Currently, only infliximab (IFX) and adalimumab (ADL) are FDA-approved for pediatric IBD, presenting unique challenges for mucosal healing (MH).
Purpose of the Study:
- To review the role and efficacy of adalimumab (ADL) in treating pediatric inflammatory bowel disease (IBD).
- To examine studies focusing on ADL's impact in children and adolescents with IBD.
- To assess ADL's effectiveness beyond clinical remission, including mucosal healing and histological remission.
Main Methods:
- Review of existing studies and clinical data on adalimumab (ADL) use in pediatric inflammatory bowel disease (IBD) populations.
- Analysis of ADL's efficacy in both biologic-naïve and previously treated pediatric patients.
- Exploration of the potential benefits of therapeutic drug monitoring (TDM) for ADL treatment optimization.
Main Results:
- Adalimumab (ADL) demonstrates efficacy in pediatric IBD patients, irrespective of prior biologic exposure.
- ADL contributes to achieving not only clinical remission but also significant mucosal healing (MH) and histological remission.
- Therapeutic drug monitoring (TDM) shows promise in enhancing ADL effectiveness and reducing treatment failure in pediatric IBD.
Conclusions:
- Adalimumab (ADL) is a valuable therapeutic option for pediatric inflammatory bowel disease (IBD), supporting comprehensive remission goals.
- The integration of therapeutic drug monitoring (TDM) is crucial for optimizing ADL treatment strategies in the 'treat-to-target' era for pediatric IBD.
- Further research into ADL and TDM can improve long-term outcomes and personalize treatment for young IBD patients.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
243
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
243
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
225
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
225
01:29Inflammatory Bowel Disease IV: Pharmacological Management
208
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
208
01:29Drugs for Treatment of Ulcerative Colitis in IBD
255
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
255
01:30Inflammatory Bowel Disease II: Crohn's Disease
414
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
414